SCHEINER, BERNHARD
 Distribuzione geografica
Continente #
AS - Asia 651
NA - Nord America 546
EU - Europa 511
SA - Sud America 104
AF - Africa 57
Totale 1.869
Nazione #
US - Stati Uniti d'America 509
RU - Federazione Russa 263
SG - Singapore 235
HK - Hong Kong 126
CN - Cina 114
BR - Brasile 80
VN - Vietnam 59
FR - Francia 44
BJ - Benin 42
DE - Germania 41
GB - Regno Unito 35
IT - Italia 29
AT - Austria 27
IN - India 24
KR - Corea 24
CA - Canada 18
JP - Giappone 18
AR - Argentina 13
BD - Bangladesh 13
MX - Messico 13
IQ - Iraq 10
NL - Olanda 9
PL - Polonia 9
SE - Svezia 9
UA - Ucraina 9
FI - Finlandia 8
ZA - Sudafrica 8
ES - Italia 6
IE - Irlanda 6
LT - Lituania 6
EC - Ecuador 5
CH - Svizzera 4
TR - Turchia 4
CO - Colombia 3
MA - Marocco 3
PH - Filippine 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
JM - Giamaica 2
NP - Nepal 2
PT - Portogallo 2
SA - Arabia Saudita 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EG - Egitto 1
GE - Georgia 1
ID - Indonesia 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
PK - Pakistan 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 1.869
Città #
Singapore 127
San Jose 126
Hong Kong 122
Ashburn 79
Cotonou 42
Los Angeles 38
Beijing 33
Moscow 29
Lauterbourg 25
Seoul 24
Buffalo 16
Falkenstein 16
Ho Chi Minh City 16
Santa Clara 16
Tokyo 16
Vienna 15
New York 14
São Paulo 14
Orem 13
Hanoi 10
Nuremberg 10
Brooklyn 9
Denver 9
London 9
Stockholm 9
Warsaw 9
Chicago 8
Frankfurt am Main 8
Boston 7
Chennai 7
Dublin 7
Helsinki 7
Mexico City 7
Tianjin 7
Assago 6
Phoenix 6
Da Nang 5
Dhaka 5
Johannesburg 5
Manchester 5
Poplar 5
Toronto 5
Amsterdam 4
Houston 4
Montreal 4
Shenzhen 4
Zurich 4
Ankara 3
Atlanta 3
Baie-D'Urfé 3
Boardman 3
Dallas 3
Elk Grove Village 3
Honolulu 3
Mumbai 3
Roubaix 3
Sorocaba 3
Turin 3
Uberlândia 3
Baghdad 2
Basra 2
Bexley 2
Calgary 2
Cape Town 2
Cleveland 2
Council Bluffs 2
Deiva Marina 2
Delhi 2
Guangzhou 2
Guayaquil 2
Haiphong 2
Hải Dương 2
Ludhiana 2
Manassas 2
Manila 2
Medellín 2
Montevideo 2
Najaf 2
New Delhi 2
Ninh Bình 2
Paris 2
Querétaro 2
Quito 2
Raleigh 2
Ryazan 2
Santa Fe 2
Seattle 2
Secaucus 2
Shanghai 2
Taubaté 2
Agrolândia 1
Aguascalientes 1
Aktobe 1
Algiers 1
Alvorada 1
Amritsar 1
América 1
Apodaca 1
Apollo 1
Apucarana 1
Totale 1.074
Nome #
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 112
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 102
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 86
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 83
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 81
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 80
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 76
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 75
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 74
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 73
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 72
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 72
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 66
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) 66
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 65
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 63
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 62
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 62
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 61
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy 59
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study 59
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 59
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 55
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 55
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 45
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy 41
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune Control 40
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 33
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 26
Totale 1.903
Categoria #
all - tutte 8.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.290


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202459 16 1 6 1 8 0 8 4 0 1 0 14
2024/2025468 8 0 30 2 6 35 57 60 102 58 22 88
2025/20261.376 64 43 79 165 217 129 234 204 125 116 0 0
Totale 1.903